CALML5 (Gene)

Organism:

Homo sapiens

Taxonomy (Entity type)

Synonyms:CALML5, CLSP, ENTREZ:51806, HGNC:18180, MIM:605183, NM_017422, NP_059118, calmodulin like 5

Omim:OMIM:605183

Id:ENSG00000178372

Hgnc:HGNC:18180

Entrez:51806

Ensembl:ENSG00000178372

Description:calmodulin like 5

This gene encodes a novel calcium binding protein expressed in the epidermis and related to the calmodulin family of calcium binding proteins. Functional studies with recombinant protein demonstrate it does bind calcium and undergoes a conformational change when it does so. Abundant expression is detected only in reconstructed epidermis and is restricted to differentiating keratinocytes. In addition, it can associate with transglutaminase 3, shown to be a key enzyme in the terminal differentiation of keratinocytes. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CALML5's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CALML5.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CALML5.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CALML5.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CALML5.

Results found

Linked to

	Label	Description
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE82032 trametinib HCC1143 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 fulvestrant 10 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 1 V 6 FULVESTRANT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE82032 3 V 1 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 7 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 10 V 6 FULVESTRANT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 fulvestrant 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988,GSE216989 0 V 1 DECITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE82032 trametinib HCC1143 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216540 fulvestrant 10 v 6 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216540 1 V 6 FULVESTRANT HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE82032 3 V 1 TRAMETINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE252944 AKT inhibition 7 v 15 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216540 10 V 6 FULVESTRANT HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE216540 fulvestrant 0 v 6 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216988,GSE216989 0 V 1 DECITABINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.